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Eye Tissue Regeneration: SEAM as a Cure For Prevalent Eye Diseases 
Introduction 
Embryonic stem cells were not harvested successfully from human embryos until 
1998 (Yu J and Thomson JA 2016). For a scientific discovery that is relatively new, the 
use of stem cells, particularly embryonic stem cells, has caused its fair share of intense, 
world-wide controversy. It seems as if every other year, the United States government is 
changing its stance on stem cell research. Funding will be redacted for years, and then 
low and behold more funding will be given than ever before. For the short time that stem 
cells have been researched, they have caused a whirlwind of political events and have 
been on a rollercoaster of scientific breakthroughs and hiatuses due to the 
government’s wavering stance on their research. The debate on the ethics of stem cells 
is climbing its way up to the top of some of the world’s most controversial topics like gay 
rights and abortion. While the war on stem cells continues to rage on, some of the most 
promising disease cure options are being discovered through the use of stem cells. So 
while some might argue that the use of stem cells can cause great harm, science is also 
finding uses for them that will enhance the greater good. An area of disease that stem 
cell therapy shows promise in is eye diseases. In 2016, biologists from the University of 
Japan discovered the use of induced pluripotent stem cells (IPSCs) to regenerate eye 
tissue by making a self-formed ectodermal autonomous multizone, which is commonly 
abbreviated to SEAM (Hayashi et al. 2016). The SEAM of ocular cells mimics the 
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development of a human eye due to the fact that the cells form different zones that 
make up the whole eye as an entire organ (Hayashi et al. 2016). The SEAM of ocular 
cells that is still being researched and tested on in animal models is revealing itself to be 
a one day, promising cure for many of the eye diseases people of the world face today. 
Some of the most promising applications of eye tissue regeneration through a SEAM 
are for uses in people with diseases like corneal blindness, macular degeneration, and 
limbal stem cell deficiency. The SEAM that is being researched would not be possible 
without stem cells and all of the research that has been conducted to further their 
scientific advancement over the years. This review will discuss the history of stem cells, 
due to the SEAM being reliant on them, making their histories intertwined. Applications 
of the SEAM as a cure for the eye diseases aforementioned will also be discussed. 
Finally, the mechanisms behind the SEAM will be evaluated in order to determine if it is 
a viable solution to the outlined eye diseases. 
History of Stem Cells: Scientific 
 SEAM was first discussed in a 2016 study published by Nature. The study 
described the use of induced pluripotent adult stem cells in making a SEAM of 
regenerative eye tissue (Hayashi et al. 2016). While using stem cells for regenerating 
tissues might seem like old news, the history of stem cells does not actually date back 
to that long ago. IPSCs, the cells of current interest while producing a SEAM, were not 
produced until 2007, a mere nine years before the discovery of SEAM.  
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 While IPSCs were discovered relatively recently, the use of stem cells for human 
cell and tissue therapy was first done in the 1950s. Bone marrow transplants were the 
first type of human adult stem cell transplants to be performed. While the first 
transplants were done between identical twins, later on using the knowledge of human 
leukocyte antigen matching in the 1970s, transplants were able to be done between 
non-related donors and recipients (Glicksman 2018). Human leukocyte antigens are 
proteins that reside on cell surfaces and have to be matched during tissue transplants 
so that the recipient does not reject the donor (Scaradavou 2013). The adult stem cells 
used for marrow transplants do not have pluripotency, so they do have limitations in 
regards to what tissues they can generate into. This is why the harvesting of human 
embryonic cells in 1998 was a great step for regenerative medicine: embryonic stem 
cells are pluripotent and have the ability to differentiate into the 3 germ layers of the 
body, giving them the potential to give rise to nearly all cell types of a human 
(Dabrowska and Skopinski 2017). While embryonic stem cells have many practical 
applications, they have caused a great deal of controversy, due to the fact that obtaining 
them leads to the destruction of human embryos. 
 
History of Stem Cells: Political 
The controversy behind stem cells is a major component of their history, as well 
as the history of any technology produced via stem cells in the years after their 
 Bute 4 
discovery. This review will examine the political history of stem cells in the United 
States, taking into account that stem cell policies differ around the world, attributable to 
controversial nature. Much of the political debate in the United States regarding stem 
cells is caused by research on embryos; however, induced pluripotent stem cells, the 
stem cell of interest in this review, has caused some political strife as well.  
Examining political controversy chronologically, a major point in stem cell history 
was the 2001 ban of federal funding on embryonic stem cell research outside of an 
existing 60 stem cells lines, enacted by former president George W. Bush (Timeline... 
2015). This executive order, as to be expected, halted many applications of stem cell 
therapy in regenerative medicine on account of lack of research. In both 2005 and 2007, 
congress attempted to pass a Stem Cell Research Enhancement Act, allowing for 
research to continue on embryos made for, but not used in in vitro fertilization. While 
these acts were strongly favored by the House and Senate, both acts were vetoed by 
Bush (Timeline... 2015). It was not until 2009 that former president Obama reversed the 
2001 ban on embryonic research, and federal funding was given back to embryonic 
stem cell research (Stem Cells… 2018). Stem cell research laws and funding still 
remain similar to 2009 in the year this review is being written, but as it can be seen from 
stem cells political history, laws are always subject to change (Tarne 2018). 
Seeing as embryonic stem cell use has brought up a lot of debate in the past, 
many scientists try to use adult stem cells when making therapies and treatments that 
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they hope one day will be available to the public (Tarne 2018). IPSCs have been a topic 
of focus in the years since they were first discovered in 2007. IPSCs are derived from 
adult somatic cells, commonly skin fibroblasts, and are reprogrammed to pluripotency 
so that they are able to proliferate unlimitedly, and be differentiated into cells from the 
three germ layers of the human body (Glicksman 2018). IPSCs however, have not been 
able to escape from political controversy unscathed, although many consider them a 
better alternative to the use of embryonic cells. 
Many advocates against embryonic stem cell research are also not in favor of the 
use of IPSCs due to something coined “gameteless reproduction” (Hoberg 2013). It is 
projected that eventually stem cell researchers will be able to derive an embryo from 
IPSCs by differentiating adult cells into egg and sperm (Hoberg 2013). This is why the 
word “gameteless reproduction” is being used; because gametes would never be used 
from a person, but instead made through the use of stem cells ex vivo. Critics of IPSCs 
claim that “gameteless reproduction” will only contribute to the current debate over 
human cloning, as well as bring up new moral and legal issues that the world has had 
yet to face (Hoberg 2013). While the controversy regarding stem cells continues, so 
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Anatomy and Physiology of the Human Eye 
Since this review will discuss several diseases and infections that affect different 
areas of the eye, general eye anatomy and physiology of structures pertaining to the 
diseases are important to include for clarity.   Every part of the eye from the eyelashes 
to the optic nerve are essential in providing humans with adequate vision. Starting with 
anterior structures and moving posteriorly, the conjunctiva is the outermost layer of the 
eye and it contains the sclera, which is the white portion of the eyeball. The conjunctiva 
acts to protect the eye from getting bacteria and debris behind it, and the sclera acts to 
give the eye structure and shape. Still in the outer layer of the eye, the cornea acts as a 
focus tool for light as it enters the eye. A healthy cornea is clear so that light can 
properly funnel through it. Located just behind the cornea is the iris, the colored part of 
the eye. This structure contracts and expands depending on the amount of light coming 
into the pupil located at the center of it. Behind the pupil and iris is the lens, which works 
together along with the cornea to focus light onto the retina. Located in the very back of 
the eye is the retina. The retina contains cells called rods and cones which are 
receptors for light and color respectively. The rods and cones act to create a visible 
image by sending signals to the optic nerve, which carries these signals to the brain to 
be turned into images. The macula is the part of the central retina that has a high 
concentration of cones, which enables sharp, central vision (Anatomy… 2018). 
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A SEAM of Ocular Cells Formed by IPSCs 
The areas of the eye mentioned in the above section are all areas of the eye that can be 
produced by forming a SEAM. In the 2016 study published by Nature, researchers 
published their findings on SEAM; including how the SEAM was made, what areas of 
the eye it was representative of, and animal trials that were conducted using the tissue 
generated by SEAM. A SEAM is produced by cultivating tissues from IPSCs that 
represent 4 different concentric zones of the eye (Hayashi et al. 2016). The zones have 
characteristics of the ocular surface, the lens, the neural retina, and the retinal pigment 
epithelium (Fuest and Mehta 2016). Zone 1 of the SEAM represents the 
neuroectoderm, from which the retina develops. Zone 2 of the SEAM represents the  
retinal pigment epithelium, neural crest, and neuro-retina. The iris and the stroma of the 
cornea both have origins in the neural crest, representative of zone 2. Zone 3 of the 
SEAM represents the ocular surface epithelium, where corneal epithelial cells are 
located. Zone 3 was shown to have characteristics of corneal, limbal, and conjunctival 
epithelial cells. Finally, zone 4 represents general surface ectodermal cells, which are 
likely to differentiate into epidermal keratinocytes. These keratinocytes are 
representative of the cell type that is found in the epidermis of any skin on the body 
(Hayashi et al. 2016). 
In the original study that described SEAM, the researchers stated that their goal 
was not to form retinal tissue. Production of retinal tissue through IPSCs had been done 
 Bute 8 
before; therefore, their goal was to generate corneal epithelial tissue that could be 
transplanted after being produced ex vivo. Although the goal of the experiment was not 
to form retinal tissue, SEAM represents the formation of an entire eye from the posterior 
retinal to the anterior ocular surface. Zone 3 is the major area of interest in this study, 
and the data of the study collectively showed that zone 3 had characteristics that could 
be used to produce ocular epithelial tissue that have potential be used in human 
surgical situations in the future (Hayashi et al. 2016). Another unique feature of the 
SEAM that was created compared to other studies attempting to produce corneal tissue, 
was that feeder cells were not used. Feeder cells are normally used to support the 
growth of stem cells like the IPSCs being used in the study, however they were not 
used in the production of a SEAM, giving the Hayashi et al. study an advantage. The 
use of feeder cells can lead to the impurity of the cells that are trying to be grown. In 
previous studies, IPSCs were induced to be corneal epithelial-like, but since feeder cells 
were used, they were never able to fully differentiate and develop into completely pure 
corneal epithelial cells. Moreover, the corneal epithelial stem cells that are produced by 
the SEAM are purified through the use of antibodies. These characteristics of the 
methods used to generate a SEAM give them an advantage in future clinical trials 
because the corneal cells derived from the SEAM will not have impurities that could 
have come from feeder cells (Hayashi et al. 2017). 
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In the Hayashi et al. study, rabbits were used to demonstrate the applications of 
transplanting eye tissue made from the production of a SEAM. Female rabbits were 
used in this experiment, and they were induced to have corneal stem cell deficiencies in 
order to blind them. Creating the epithelial-limbal stem cell deficiency was done through 
a corneal and limbal lamellar keratectomy, which removed the rabbits’ ocular epithelial 
tissue. The rabbits were then given corneal grafts from the corneal epithelial stem cells 
created through making a SEAM. The corneal sheets that were transplanted onto the 
damaged rabbit eyes were able to regain function and restore sight to the rabbits. The 
study stresses the point that this specific type of ocular surface tissue regeneration is a 
novel idea, because previous studies have only used somatic cells to regain corneal 
function with the long-term outcomes not having much promise (Hayashi et al. 2016). 
The experiment performed by Hayashi et al. has been discussed in several review and 
editorial articles all praising the groundbreaking science, as well as outlining some of 
the potential complications with the advanced eye research. 
Limitations and Potential Solutions 
In a 2018 review article by Sasamoto et al., some limitations of using SEAM for 
eye regeneration are discussed. Although human trials using SEAM have not yet been 
conducted, high cost of the technology is already being considered as a potential 
drawback. Producing a SEAM is reliant upon the use of IPSCs. In order to properly 
obtain the IPSCs, appropriate techniques must be followed to acquire viable cells. Most 
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research involving stem cells is costly due to the advanced nature of it. Additionally, 
after the corneal sheets are transplanted into the eyes of the recipient, strict eye drop 
regimens must be followed and time must be allowed for the sheets to differentiate into 
new corneal epithelial cells. Therefore, another drawback of SEAM that is considered is 
the amount of time it takes to produce IPSCs, as well as the time it takes to produce a 
SEAM. According to another editorial article, the transplanted epithelial cells take about 
13-18 weeks to differentiate to their mature potential as corneal epithelial cells (Fuest 
and Mehta 2016). Another risk potential that has been cited is the potential for 
tumorigenicity of cells that have developed from IPSCs. This higher risk for 
tumorigenicity comes from uncontrolled growth of the IPSCs (Sasamoto et al. 2016). 
Like many experiments in the early stages of trials, there are still areas of SEAM that 
need to be improved to gain full benefits from it in the future. 
 Potential solutions to the drawbacks mentioned above are already being 
formulated in order to perfect the use of IPSCs in making a SEAM. In regards to the 
lengthy process of obtaining IPSCs and making a SEAM, as well as the high costs of 
both of these processes, a solution that has been suggested is the creation of human 
leukocyte antigen (HLA)-typed IPSC banks (Sasamoto et al.). Mentioned earlier in this 
article, human leukocyte antigens are cell surface proteins that can be matched in 
donor-recipient situations. While taking cells directly from the patients to make IPSCs 
for them that can be made into a SEAM has benefits like low chance of rejection, using 
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HLA banks to stem cell match could be more financially and time feasible (Taylor 2012). 
As for the increased chance of tumorigenicity, suggestions have been made to use 
direct reprogramming of cells as opposed to IPSCs. In the article by Sasamoto et al., 
some cell types are discussed that would good candidates for reprogramming. Cells 
that are being considered as having promising potential to be reprogrammed include: 
bone marrow mesenchymal cells, hair follicle stem cells, skin epithelial stem cells, 
dental pulp stem cell sheets, and nasal mucosal epithelial cell sheets (Sasamoto et al. 
2016). Although there are still modifications that need to be made to SEAM to make it 
more financially and medically dependable, researchers have high hopes for its future 
and are preparing for the next stages of starting human trials after their successful trials 
on the rabbits (Fuest and Mehta 2018).  
SEAM applications in Limbal Stem Cell Deficiency 
Cause of Limbal Stem Cell Deficiency 
In the Nature study described above, limbal stem cell deficiency was induced in 
rabbits in order to test the effectiveness of corneal epithelial sheets produced by SEAM; 
however limbal stem cell deficiency a condition that affects humans too. The outer layer 
of the corneal epithelium is essential for vision, and it needs to constantly renewed with 
corneal stem cells. This is due to the need of the cornea to stay transparent, for 
effective vision to be achieved. The stem cells that are crucial for keeping the cornea 
functioning properly are located in cornea-conjunctival transition zone, commonly 
referred to as the limbus. When there is damage to the limbal area or cornea, as 
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demonstrated on the rabbits in the Hayashi et al. experiment, this can result in severe 
vision loss or even total blindness. The vision loss is a consequence of the formation of 
conjunctival epithelium (Selver et al. 2017). The conjunctival tissue replaces the 
normally transparent corneal surface with hazy tissue. Limbal stem cell deficiencies can 
arise from several factors and can affect anyone in the world. Limbal stem cell 
deficiency can be acquired by having burns or trauma to the eye, inflammatory 
diseases, and genetic diseases, and even the overuse of contact lenses (Sasamoto et 
al. 2018) . While limbal stem cell deficiency is an extremely painful and enervating 
disease, treatment of limbal stem cell deficiency is currently hard to come by, and does 
not offer the most promising of outcomes (Ahmad 2012). 
Current Treatments for Limbal Stem Cell Deficiency 
Before limbal stem cell deficiency can even begin to be treated, it first has to be 
diagnosed. Often times, limbal stem cell deficiency is not properly diagnosed and a 
corneal transplant is given as treatment, and this does not result in desired outcomes. If 
the disease does happen to be properly diagnosed, tribulations are still faced in order to 
try and alleviate its symptoms. Limbal cell transplantation is one of the current 
treatments for this disease. This involves taking tissue from a donor eye and 
transplanting it into the affected individual. However, there is quite a lot of risk to the 
donor during this procedure, so only a small amount of tissue can be obtained. Even if 
tissue is successfully taken from a donor eye, the donor can be left with complications 
like scarring, chronic inflammation, discomfort, as well as infection (Fuest and Mehta 
2016). Donor shortage is also a significant issue when it comes to limbal stem cell 
deficiency (Research… 2016).  In the miniscule amount of tissue that can actually be 
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taken from the donor, an even smaller percentage of this tissue actually contains limbal 
stem cells (Selver et al. 2017). Cells donated from cadavers have also been considered 
as a treatment option, but these have shortcomings as well. In the case of 
transplantation from either living or dead donors, recipients often need long-term 
immunosuppression so that they do not reject the donated tissue (Fuest and Mehta). 
While improvements in the damaged eye are sometimes seen short term, current 
treatments often are not shown to last over the long term (Ahmad 2012).  
SEAM as a Novel Treatment for Limbal Stem Cell Deficiency 
The rabbits in the 2016 Nature study are a glimpse into the future for the cure of 
limbal stem deficiency in humans. By growing corneal sheets from cells made in the 
third zone of SEAM, sight was restored in the limbal stem cell deficient rabbits. The 
researchers behind this experiment concluded their article with the statement that they 
are working on preparing SEAM to be ready for the use on humans (Hayashi et al. 
2016). One of the major benefits of using SEAM to replenish corneal stem cells is that 
IPSCs are behind the mechanism of tissue regeneration. As mentioned before, IPSCs 
are not always time efficient, but they are a much more viable option compared to the 
method of donated tissue that is currently being used. This is a result of the fact that 
IPSCs can be made from adult cells gathered from the person who has the deficiency to 
begin with. The stem cells that are taken from the individual affected with the deficiency 
can be induced to pluripotency, and then made into a SEAM, which eliminates the 
potential for immunological rejection. Not only is the issue of rejection solved by using 
epithelial cells created by the SEAM, but the need for a donor would also be taken off 
the table (Research… 2016). Hereby, using cells created by the SEAM is a solution to 
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the major issues, and associated long-term complications, that are currently involved in 
the treatment of limbal stem cell deficiency. 
Use of a SEAM to regenerate corneal cells: Potential Cure of Corneal Blindness 
Cause and Prevalence of Corneal Blindness 
Limbal Stem Cell Deficiency is a leading cause of the greater, overarching issue 
that is corneal blindness, which affects over six-million people around the world (Selver 
2016). The prevalence of corneal blindness differs vastly in different areas around the 
world due to factors that will be further discussed later in this review. Corneal blindness 
is one of the world’s leading causes of blindness after cataracts, glaucoma, and macular 
degeneration (Wong et al. 2017). There are several causes of corneal blindness, but it 
most often occurs as a consequence of infection and inflammation. Blindness is brought 
on due to scarring on the cornea from the vast list of infections and diseases that lead to 
corneal blindness (Whitcher et al. 2001). This review will focus on trachoma as an 
example of an infection that ultimately causes corneal blindness, due to the large 
amount of individuals it affects, having visually impaired an estimated 2.2 million 
individuals worldwide, with 1.2 of these people left completely blinded (Boyd 2015). 
 Trachoma is an infection of both eyes caused the bacteria Chlamydia 
trachomatis. While trachoma is easily treatable in the developed world, people in 
developing countries who do not have proper access to medical attention are at a much 
higher risk for the infection to leave them completely blind. Furthermore, statistics have 
shown that mostly women and children make up the population of people with active 
trachoma infections. If trachoma is not treated properly, corneal scarring can occur 
because the eyelashes will turn into the eye and scratch and irritate the cornea. This will 
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eventually lead to enough scratching and irritation that the cornea clouds over, and is no 
longer viable to see out of (Boyd 2015). 
Current Treatments for Corneal Blindness 
 Trachoma and several other eye diseases have left millions around the world 
without sight; and unfortunately, many of these people will stay blind forever due to the 
limited amount of treatment currently available to them. Corneal transplantation and 
corneal grafts are the current cure for corneal blindness, but there is an extreme 
shortage of donors, as well as limited resources to obtain and properly store the 
donated corneas. As opposed to the limbal stem cells, corneal donations do not usually 
have to be matched from donor to recipient to evade rejection. While this does make 
transplantations easier, in 2012 there was only about one donated cornea for every 70 
people in need of one (Wong et al. 2017). Not only are there not enough corneas 
available, but there are also a shortage of corneal surgeons around the world who are 
trained to perform the transplantation surgeries (Oliva et al. 2012). Furthermore, access 
to eye banks, where donated corneas are stored also poses an issue. If corneas 
happen to get donated, they have to be stored properly and time sensitivity plays a key 
role in maintaining viable tissue. All around the world, there is a lack of notification 
systems to alert facilities that are capable of storing the donated tissues. If too much 
time has passed, the corneas will no longer be able to be transplanted into a donor, and 
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Corneal Tissue Obtained from a SEAM as a Cure for Corneal Blindness 
As it can be inferred from the current treatments section above, many of the 
issues regarding corneal transplants revolve around lack of donations and how the 
donations are received. Using tissue produced by the third zone of the SEAM could take 
out many of the human factors that are inhibiting the current treatment models. Clear 
corneal sheets were produced from cells taken from the third zone (Herkewitz 2016). 
While corneas produced from a SEAM are still in their preliminary research phase, 
having only been experimented on animals thus far, they are a promising technique for 
the future. The use of a SEAM could solve the issue of time sensitivity because the 
corneas are purposefully being grown, so lack the lack of notification of donor tissue 
would not be applicable. Furthermore, as time progresses, and researchers perfect the 
craft of making a SEAM, corneas will not have to be donated. As of now, corneas are 
being donated by cadavers to people in need, but with the use of a SEAM, they can be 
grown for people in need using cells taken from their own body. While SEAM is not yet 
ready to provide the world with the corneas it needs yet, it is quite possible in the near 
future that it could be a revolutionary treatment for the millions suffering from corneal 
blindness. 
Use of a SEAM to regenerate retinal cells: Potential Cure of Macular Degeneration 
Cause of Macular Degeneration 
Macular degeneration comes in two forms, wet and dry macular degeneration, 
and it is age related. Most people suffering from macular degeneration have dry 
macular degeneration. The underlying cause of dry macular degeneration is not known. 
However, it is known that deposits on the retina and behind the macula form and cause 
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the macula to deteriorate over time. Once a person has dry macular degeneration, it 
affects both eyes, but can progress at different rates in each eye. As for wet macular 
degeneration, around 10-15% with macular degeneration have the wet type. Although 
less people have wet macular degeneration, it is the type that causes more severe 
vision loss. Wet macular degeneration causes blood vessels under the retina to grow 
towards the macula. These blood vessels tend to break and bleed, causing damage to 
the macula which make the macula detach from its base. When the macula detaches, 
central vision is lost quickly and to a great extent. Unlike many other eye diseases, 
there are no current cures or treatments that exist at all for either types of macular 
degeneration (Mogk 2018). As a leading cause of vision loss around the world, a cure 
for macular degeneration desperately needs to be developed, and SEAM could be that 
cure. 
SEAM as a Potential Cure for Macular Degeneration 
While the researchers who originally produced the SEAM were focused on 
making corneal tissue, they also managed to construct cells that form into retinal tissue 
as well. As previously mentioned, the second zone of the SEAM consists of cells 
representative of the retinal pigment epithelium and neuroretina (Fuest and Mehta 
2016). Therefore, SEAM has the potential to reconstruct retinal tissue that has been 
damaged through macular degeneration, which will allow for transplantation of retinal 
tissue that has been constructed ex vivo. Once again, the issue of rejection does not 
have to be considered with SEAM, because if need be, the IPSCs can be produced 
from the recipient's own cells. (Research 2016). Looking further into the future of SEAM, 
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the world is one step closer to growing an entire human eyeball in a lab, which will hold 
potential cures for even the incurable, like macular degeneration.  
Conclusion 
The research that has been presented in this review is still in its early stages of 
development; however, this does not take away from the fact that it needs to be taken 
into serious consideration by the scientific and medical communities. Producing a 
SEAM through the use of induced pluripotent stem cells is a potential cure for many eye 
diseases that rob millions of sight around the world today. The original researchers who 
first produced the SEAM published a follow-up article, again in Nature, which described 
how the production of a SEAM will add to a greater understanding of the human eye as 
it is currently known. The 2017 Nature article sheds light on the fact that while the 
SEAM is still in its days of infancy, it is lending a hand to understanding the origins of 
the different tissues that make up the human eye. Therefore, while its clinical 
applications are still in the works, a SEAM is acting as a tool for the study of more 
fundamental eye tissues. Curing diseases through structures produced by a SEAM can 
be expected in future years to come, but in the present, a SEAM will provide scientists 
with an expanded knowledge of human eye tissues in the earliest of developments 
(Hayashi et al. 2017).  While funding might be scarcer than needed for stem cells and 
regenerative medicine, while there are health risks that need to be considered, and 
while time is always against the scientists devoting their lives to this research; SEAM is 
a worthwhile endeavor that has the potential to improve the lives of millions.  
 
 
 Bute 19 
 Works Cited 
1. Ahmad, S. 2012 Feb. Concise Review: Limbal Stem Cell Deficiency, Dysfunction, 
and Distress. Stem Cells Translat Med [serial online].1(2):110–115. Available 
from: NCBI. 
2. Barut SÖ, Yağcı A, Eğrilmez S, Gürdal M, Palamar M, Çavuşoğlu T, Ateş U, 
Veral A, Güven Ç, Wolosin JM. 2017. Limbal stem cell deficiency and treatment 
with stem cell transplantation. Turkish Journal of Ophthalmology [serial online]. 
47(5):285-91. Available from: NCBI. 
3. Boyd K. What Is Trachoma? [Internet]. 2015 Oct 14. American Academy of 
Opthamology; [cited 2018 Oct 5,]. Available from: https://www.aao.org/eye-
health/diseases/what-is-trachoma. 
4. Fuest M, Mehta JS. 2016 Sept 19. In vitro eye embryogenesis from induced 
pluripotent stem cells for ocular surface disease treatment. Yan Ke Xue Bao 
[serial online]. [cited 2018 Sep 26]; 31(4): 230-233. Available from ILL. 
5. Glicksman MA. 2018 July. Induced Pluripotent Stem Cells: The Most Versatile 
Source for Stem Cell Therapy. Clinic Thera [serial online]. [2018 Sept 23]; 40(7): 
1060-1065. Available from: Science Direct. 
6. Hayashi R, Y Ishikawa, Y Sasamoto, R Katori, N Nomura, T Ichikawa, S Araki, T 
Soma, S Kawasaki, K Sekiguchi, AJ Quantock, M Tsujikawa, K Nishida. 2016 
Mar 17. Co-ordinated ocular development from human iPS cells and recovery of 
 Bute 20 
corneal function. Nature [serial online]. [cited 2018 Sept 22]; 531(1): 376-381. 
Available from ILL. 
7. Hayashi R, Y Ishikawa, R Katori, Y Sasamoto, Y Taniwaki, H Takayanagi, M 
Tsujikawa, K Sekiguchi, AJ Quantock, K Nishida. 2017. Coordinated generation 
of multiple ocular-like cell lineages and fabrication of functional corneal epithelial 
cell sheets from human iPS cells. Nature Protocol [serial online]. [cited 2018 Oct 
18];12(4): 683-696. Available from ILL. 
8. Herkewitz W. Stem Cell Breakthrough Could Let Us Grow New Human Eyes. 
[Internet]. 2016 March 9. Popular Mechanics; [2018 Sept 22]. Available 
from: https://www.popularmechanics.com/science/health/a19856/lab-grown-
human-eyes-are-coming-into-focus.  
9. Hoberg M. 2013. Reprogrammed adult stem cells raise new ethical issues 
[internet]. S. C. Hunnicutt (Ed.). Detroit: Greenhaven Press; [2018 Sept 23]. 
Available from: GALE Opposing Viewpoints  
10. Human Eye Anatomy & Physiology Diagram [Internet]. 2018. Emedicine from 
WebMD; [cited 2018 Oct 4,]. Available 
from: https://www.emedicinehealth.com/anatomy_of_the_eye/article_em.htm. 
11. Mogk LG. The Difference Between Wet and Dry Age-Related Macular 
Degeneration.  [internet]. 2018. Vision Aware; [cited 2018 Oct 5]. Available 
 Bute 21 
from: http://www.visionaware.org/info/your-eye-condition/age-related-macular-
degeneration-amd/wet-and-dry-amd/125. 
12. Mogk LG. What Treatments are Available for Dry Macular Degeneration. 
[internet]. 2018. Vision Aware; [cited 2018 Oct 5]. Available 
from: http://www.visionaware.org/info/your-eye-condition/age-related-macular-
degeneration-amd/treatments-for-dry-macular-degeneration/125. 
13. Oliva MS, Schottman T, Gulati M. 2012. Turning the tide of corneal blindness. Ind 
Journ of Ophth, [cited 2018 Oct 14]; 60(5), 423–427. Available from: NCBI. 
14. Sasamoto Y, BR Ksander, MH Frank, NY Frank. 2018 Mar 6. Repairing the 
corneal epithelium using limbal stem cells or alternative cell-based therapies. Exp 
Opin on Bio Ther [serial online]. [cited 2018 Sept 26]; 18(5): 505-513. Available 
from ILL. 
15. Scaradavou A. 2013. Transfusion Medicine and Homeostasis. 2nd Ed. Elsevier 
Science.  Available from: Science Direct. 
16. Stem Cells Fast Facts [Internet]. 2018 Jul 17. CNN; [cited 2018 Sep 30,]. 
Available from: https://www.cnn.com/2013/07/05/health/stem-cells-fast-
facts/index.html. 
17. Successful mimicking of ocular development with human iPS cells and 
generation of corneal epithelium [Internet]. 2016 Mar 10. Research at Osaka 
 Bute 22 
University; [cited 2018 Oct 5]. Available from: http://resou.osaka-
u.ac.jp/en/research/2016/20160310_2. 
18. Tarne, E. Trends Show More Federal Funds Awarded to Non-Embryonic Stem 
Cell Research [Internet]. 2018 Feb 8. Charlotte Lozier Institute; [cited 2018 Oct 
3]. Available from: https://lozierinstitute.org/trends-show-more-federal-funds-
awarded-to-non-embryonic-stem-cell-research/. 
19. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. 2012 Aug 3. 
Generating an iPSC bank for HLA-matched tissue transplantation based on 
known donor and recipient HLA types. Cell Stem Cell [serial online]. [cited 2018 
Oct 6];11(2):147– 152. Available from PubMed. 
20. Timeline of major events in stem cell research policy [Internet]. 2015. Research 
America; [cited 2018 Sep 30]. Available 
from: https://www.researchamerica.org/advocacy-action/issues-researchamerica-
advocates/stem-cell-research/timeline-major-events-stem-cell. 
21. Upadhyay MP, Whitcher JP, Srinivasan M. 2001. Corneal blindness: A global 
perspective. Bulletin of the World Health Organization 79(3):214. Available 
from: https://www.scielosp.org/scielo.php?pid=S0042-
96862001000300009&script=sci_arttex. 
 Bute 23 
22. Wong KH, Kam KW, Chen LJ, Young AL. 2017. Corneal blindness and current 
major treatment concern-graft scarcity. Internatl Journ of Ophth [serial online]. 
[Cited 2018 Oct 2]; 10(7):1154-62. Available from: NCBI. 
23. Yu J, JA Thomson. Embryonic Stem Cells. [internet]. 2018. Bethesda, MD: 
National Institutes of Health; [cited 2018 Oct 3]. Available from:  
https://stemcells.nih.gov/info/Regenerative_Medicine/2006Chapter1.htm. 
 
